Alliance to add focus for Large Quantitative Models (LQMs) which are the new frontier in AI with applications in biopharma, energy and other sectors
SandboxAQ announced it has expanded its relationship with Deloitte to offer SandboxAQ’s AI LQM simulation products and solutions along with Deloitte’s services capabilities to organizations worldwide.
SandboxAQ’s AQBioSim and AQChemSim solutions leverage Large Quantitative Models (LQMs) to accelerate product development across a broad range of sectors, including biopharma. Deloitte will augment these offerings with their data and life sciences experience combined with their deep business and technology acumen. This collaboration will help transform nearly every facet of healthcare and life sciences.
“SandboxAQ is excited to expand its long-standing strategic alliance with Deloitte, whose relationships with some of the world’s largest organizations will accelerate the adoption of our quantitative AI technologies,” said Andrew McLaughlin, Chief Operating Officer of SandboxAQ. “AI simulation with Large Quantitative Models represents the next evolution of AI and will have a transformative impact on how organizations create value for their customers in ways that Large Language Models cannot.”
Also Read: Capgemini Unveils Gen AI to Boost the Bioeconomy
Using LQMs in collaboration with Deloitte’s Atlas AI™ knowledge graph capabilities will allow SandboxAQ’s scientists to automatically extract new clinical hypotheses from literature, highlighting only those most likely to be correct. With Atlas AI, Deloitte brings its engineering skills and industry experience
together to accelerate the drug discovery process. Deloitte’s Atlas AI team and SandboxAQ will also collaborate with pharmaceutical companies and other organizations on data evaluation, exploratory data analysis, and AI model testing and evaluation to enhance the speed and accuracy of the drug discovery processes. Along the way, SandboxAQ’s AI-powered molecular simulations will generate vast amounts of highly accurate, physics-based data, delivering new insights for drug development, target ID, and treatment response.
“With this expansion of our alliance, we’re able to combine our extensive experience in life sciences, data, and research with SandboxAQ‘s leadership in AI simulation and Large Quantitative Models,” said Aditya Kudumala, principal, Deloitte Consulting LLP. “Together, we aim to advance drug discovery and materials science for leading academic, commercial, and public sector entities.”
Source: PRNewswire
